Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent …
YH Hu, PW Wang, ST Wang, CH Lee… - Nuclear medicine …, 2004 - journals.lww.com
Background In the management of patients with differentiated thyroid carcinoma, direct
comparison of the presence of scintigraphic stunning after a diagnostic dose of 131 I with
subsequent successful ablation has not been evaluated. Methods This study included 245
patients who received a dose of 2775–3700 MBq of 131 I for thyroid remnant ablation. In all
patients, the thyroid-stimulating hormone (TSH) level before ablation was more than 30 μIU·
ml− 1. One hundred and twenty-six patients (Group A) were given a 185 MBq diagnostic …
comparison of the presence of scintigraphic stunning after a diagnostic dose of 131 I with
subsequent successful ablation has not been evaluated. Methods This study included 245
patients who received a dose of 2775–3700 MBq of 131 I for thyroid remnant ablation. In all
patients, the thyroid-stimulating hormone (TSH) level before ablation was more than 30 μIU·
ml− 1. One hundred and twenty-six patients (Group A) were given a 185 MBq diagnostic …
以上显示的是最相近的搜索结果。 查看全部搜索结果